Search Results
Results found for "Inversago Pharma"
- Addex Therapeutics To Release Full-Year 2021 Financial Results And Host Conference Call On March 10
Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical
- Actions of Parathyroid Hormone Ligand Analogues in Humanized PTH1R Knockin Mice
evaluate parathyroid hormone (PTH) and PTH-related protein (PTHrP) ligands and analogues for their pharmacologic
- Therapeutic validation of an orphan G protein-coupled receptor: The case of GPR84
of GPR84 and, in the absence of direct structural information, recent developments and use of GPR84 pharmacological
- Jan Steyaert Named 2022 Jacob and Louise Gabbay Award Winner
research in biomedical sciences with the mechanistic understanding of one of the biggest classes of pharmaceutical
- Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for...
"Geneva, Switzerland, August 15, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
"Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Addex raises $4.2 million in equity financing
Switzerland, July 22, 2022 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Michel Bouvier appointed Knight of the Ordre national du Québec
22, 2022, Michel Bouvier, Chief Executive Officer of IRIC, Principal Investigator of the Molecular Pharmacology
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
He received his undergraduate Bachelor of Science Degree in Pharmacy from The Philadelphia College of Pharmacy and Science.
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Geneva, Switzerland, April 6, 2022 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical
- Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment ...
The Phase 1 study will assess the safety, tolerability and pharmacokinetics of CFTX-1554 in healthy subjects
- Rhodopsin as a Molecular Target to Mitigate Retinitis Pigmentosa
chaperones to improve the folding and stability of the mutant receptor is one of the most promising pharmacological
- Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes
in nearly all physiological systems make GPCR the largest protein family targeted for development of pharmaceuticals
- Targeted Activation of G-Protein Coupled Receptor-Mediated Ca 2+ Signaling Drives Enhanced Cartilage
Control of chondrocyte/chondroprogenitor Ca2+ signaling has been attempted through mechanical and/or pharmacological
- Dr. Nicola J. Smith - Dr. GPCR Podcast
Nicola Smith, Molecular Pharmacologist, lab head, and senior lecturer at UNSW Sydney.
- Applications of Cryo-EM in small molecule and biologics drug design
In recent years, pharmaceutical companies have begun to utilize cryo-EM for structure-based drug design
- Obesity-induced changes in human islet G protein-coupled receptor expression: Implications for ...
GPCRs) are a large family of cell surface receptors that are the targets for many different classes of pharmacotherapy
- Phenylalanine 193 in Extracellular Loop 2 of the β 2-Adrenergic Receptor Coordinates β-Arrestin ...
that can provide insight into this aspect of GPCR signaling thanks to robust structural data and rich pharmacopeia
- TLR4 biased small molecule modulators
Biased pharmacological modulators provide potential therapeutic benefits, including greater pharmacodynamic
- Coordinated transcriptomics and peptidomics of central nervous system identify neuropeptides and ...
together, these results will benefit further investigations to determine physiological functions and pharmacological
- Melatonin MT 2 receptor is expressed and potentiates contraction in human airway smooth muscle
Activation of melatonin MT2 receptors with either pharmacological concentrations of melatonin (10-100
- VIB spin-off Confo Therapeutics Enters Collaborative Agreement with Regeneron
Confo Therapeutics today announced that it has entered into a collaborative agreement with Regeneron Pharmaceuticals
- Dr. Kevin Pfleger and Dr. Elizabeth Johnstone were awarded one of the 2022 Diabetes Research...
This $60,000 grant from Diabetes Research WA will assist the Perkins' Molecular Endocrinology and Pharmacology
